Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 8.181
- Book/Share 7.4602
- PB 5.1888
- Debt/Equity 0.0884
- CurrentRatio 3.513
- ROIC 0.232
- MktCap 10420848130.0
- FreeCF/Share 2.7473
- PFCF 13.9157
- PE 17.519
- Debt/Assets 0.0672
- DivYield 0
- ROE 0.2774
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXEL | RBC Capital Mkts | Outperform | Sector Perform | $45 | $50 | July 8, 2025 |
| Upgrade | EXEL | Stephens | Equal Weight | Overweight | -- | $60 | June 24, 2025 |
| Downgrade | EXEL | Wells Fargo | Overweight | Equal Weight | -- | $36 | Feb. 24, 2025 |
| Upgrade | EXEL | Morgan Stanley | Equal Weight | Overweight | $30 | $40 | Jan. 27, 2025 |
| Downgrade | EXEL | Oppenheimer | Outperform | Perform | -- | -- | Jan. 24, 2025 |
| Downgrade | EXEL | BMO Capital Markets | Outperform | Market Perform | $36 | $40 | Dec. 20, 2024 |
| Downgrade | EXEL | BofA Securities | Buy | Neutral | $35 | $39 | Dec. 17, 2024 |
| Reiterated | EXEL | RBC Capital Mkts | -- | Outperform | $30 | $34 | Oct. 16, 2024 |
| Initiation | EXEL | UBS | -- | Neutral | -- | $30 | Sept. 19, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Will EXEL's Share Repurchase Program Boost Value for Investors?
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Read More
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib although the size of the clinical benefit isn't known yet. Zanzalintinib doesn't seem to have outperformed in head and neck cancer, with the company curtailing development in that indication following phase 2 data from STELLAR-305.
Read More
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read More
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).
Read More
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Read More
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
Read More
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
2 Stocks to Buy With Less Than $50
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
Read More
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
Read More
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Michael M. Morrissey
- Employees 1147